Antiphospholipid syndrome is characterized by multiple arterial and/or venous thrombotic events, recurrent fetal losses in the presence of antiphospholipid antibodies (aPL). Catastrophic antiphospholipid syndrome is a life-threatening, rare subset of antiphospholipid syndrome when the thrombotic events affect at least three organs, and clinical manifestations develop simultaneously or within a week. Diagnostically, small vessel occlusions can be detected by histopathology in the presence of aPL. Our case report describes an 18-year-old man who has been treated for antiphospholipid syndrome associated with systemic lupus erythematosus (SLE) since 2011. The clinical findings were dominated by recurrent deep vein thrombosis, and severe proteinuria caused by lupus nephritis, accompanied by mild serological and laboratory findings. The patient was hospitalized in March 2014 because of severe thrombocytopenia and infective diarrhoea. At this time the renal functions deteriorated rapidly. Simultaneously, left upper extremity paresis was observed; computed tomography showed ischaemic lesions in the territory of the middle cerebral artery. Abdominal discomfort and pain occurred. On computed tomography scan ischaemic lesions were seen in the spleen, the right kidney and the coeliac trunk. Laboratory and serological findings verified the presence of aPL and anti-DNA antibodies, anaemia and thrombocytopenia. Based on the above-mentioned clinical and laboratory findings, the diagnosis of catastrophic antiphospholipid syndrome was established. Anticoagulation, corticosteroids and plasma exchange treatment, as well as haemodiafiltration were initiated. Although the thrombotic cascade decelerated following these interventions, we could not see an improvement in the renal function. Rituximab treatment was started, leading to a significant improvement in renal function. After 5 weeks of treatment the patient was discharged from hospital. Lupus (2018) 27, 1552-1558.
Introduction
Antiphospholipid syndrome (APS) is characterized by multiple arterial and/or venous thrombotic events, recurrent fetal losses in the presence of antiphospholipid antibodies (aPL). The group of aPL consists of various members, such as lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-b2-glycoprotein-I (ab2GPI) antibodies. 1, 2 Catastrophic antiphospholipid syndrome (CAPS) is a rare, severe, life-threatening subset of APS, which makes up less than 1% of all APS cases. 3 According to the CAPS registry, 59% of the patients with CAPS had APS, while 26.9% had systemic lupus erythematosus (SLE). In most of the cases, various pathogenic factors were verified, mainly infections including Salmonella, Escheria coli, Streptococcus and Staphylococcus.
According to the study by Asherson et al. 5 respiratory, cutaneous, urinary tract, gastrointestinal infections and sepsis are the commonest.
There are factors which may interfere with anticoagulation therapy, including oral contraceptives and neoplasms. It was recently reported that besides infection with thrombocytopenia, low vitamin D and high ferritin levels may also induce CAPS. 4 While the pathomechanism of CAPS in not fully understood, a series of pathogenic effects is implicated. aPL trigger a prothrombotic state, while inflammation ultimately leads to clot formation. Uncontrolled activation of the complement system can also initiate and amplify the pathological features of CAPS. Another mechanism is denoted as 'cytokine storm', which is caused by the release of proinflammatory cytokines (interleukin (IL)-1, IL-5, IL-6, interferon (IFN)-a, TNFa) from affected tissues during thrombotic events, mainly affecting the microvessels. 4 These cytokines activate the innate immune system by way of TLR-4 production, which is predominantly induced by bacterial lipopolysaccharides. 6 On the other hand, fibrinolysis is decreased, because of the high levels of plasminogen activator inhibitor-1 (PAI-1). Asherson et al. published the first diagnostic criteria for CAPS, 7 which was revised and has been in use since then. 8 According to the CAPS registry the most frequently affected organs are the kidneys, lungs, brain, heart and the skin. CAPS has a high mortality rate; before 2000 the mortality rate was 50% despite treatment. 9 The therapy addresses three aims: (a) to remove the identifiable triggering factor(s) including the infective agents (antibiotics or antiviral drugs) that improve CAPS symptoms; (b) the other crucial point is to decelerate the thrombotic cascade; and (c) to suppress the cytokine storm, which may lead to the development of systemic inflammatory response syndrome (SIRS). Therefore, the first line therapy includes anticoagulative and corticosteroid treatments. Plasma exchange and/or intravenous immunoglobulin can have favourable effects on the disease course. If CAPS is associated with autoimmune disease, mainly SLE, immunosuppression should be considered, e.g. cyclophosphamide. In refractory or relapsing cases new therapeutic options need to be applied.
Rituximab is a monoclonal antibody against CD20, which is expressed on B cells. Rituximab downregulates B-cell receptors and induces B-cell apoptosis. In turn, B-cell depletion may also reduce the production of proinflammatory cytokines, which may lead to the modulation of SIRS.
Rituximab has been approved in non-Hodgkin lymphoma, rheumatoid arthritis and SLE. There are ongoing clinical trials with rituximab in therapy-resistant non-criteria manifestations, such as thrombocytopenia, ulcers, haemolytic anaemia of APS. According to the RITAPS trial rituximab was safe in APS patients; however, rituximab has not induced changes in the aPL profile, but it was effective in non-criteria manifestations of APS. 10 According to data from the CAPS registry, rituximab reduced mortality to 20%. Kidney involvement was most frequent, followed by cardiac and cerebral involvement. Rituximab was second line therapy in 60% of the cases because of poor responses to first line therapy, recurrent CAPS, therapy-resistant thrombocytopenia or new thrombotic events or skin necrosis. [11] [12] [13] [14] [15] Eculizumab was recently successfully used in therapy-refractory cases of CAPS. 16, 17 Over the past 15 years four patients have been treated with CAPS in our department. The first was a cancer-associated CAPS case with multiple thrombotic events affecting the brain, spleen, kidneys, lungs and the mitral valve, with the presence of aCL and ab2GPI antibodies. The underlying factor was adenocarcinoma of the stomach, revealed during autopsy. 18 Our second CAPS case was also associated with malignancy: this woman was diagnosed with endometrial cancer 1 year before CAPS. Multiple thromboses developed in association with aCL IgG antibody positivity. Autopsy revealed thromboses of the pelvic vein, portal and hepatic veins and microthrombi in the spleen, respectively. 19 Our third case of CAPS was associated with SLE. Pulmonary embolism, spleen and kidney infarctions and renal occlusive vasculopathy in the small vessels were detected in association with ab2GPI IgG and anti-prothrombin antibodies. The anticoagulation and corticosteroid treatment was supplemented by high volume plasma exchange, which was synchronized by intravenous administration of immunoglobulin. The patient recovered. The fourth case of CAPS associated with SLE is the topic of this article.
Case presentation
The 19-year-old Caucasian male patient was treated for severe thrombocytopenia, indirect Coombs positivity and suffusions. Intravenous immunoglobulin was administered resulting in normalized thrombocyte level. Immunological tests showed ab2GPI, aCL and anti-phosphatydilserine antibody
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(aPS) positivities, but there was no thrombotic event at that time. In September 2010 he was diagnosed with multiple thromboses involving the right femoral vein, the common and external iliac veins, respectively. Thrombophilic tests (FII20210A, AT-III, PS and PC activity, FV Leiden, APS screening) were performed at this time and LA, IgG type aCL (50 U/ml) and IgG type ab2GPI (60 U/ml) antibodies were identified again. Oral anticoagulant therapy with vitamin K antagonist was started. In 2011 he was diagnosed with SLE based on photosensitivity, lupus erythema and the presence of antinuclear, anti-SSA, anti-SSB, anti-CL antibodies and hypo-complementemia as well, all reflecting positive LA. Hence, the diagnosis of APS associated with SLE was also established based on the clinical picture and laboratory findings. The maintenance therapy comprised corticosteroids, hydroxycloroquine and anticoagulation. During the following 2 years he had been in remission with no significant kidney abnormalities. However, he had mild symptoms of arthralgia, skin involvement and mild upper airway tract infections.
During the autumn of 2013 he was hospitalized several times because of high blood sedimentation rate, massive proteinuria (10 g/day), striking pitting oedema on the legs, increasing levels of carbamide, creatinine, worsening anaemia and thrombocytopenia, respectively. After pulse corticosteroid treatments (3 Â 1000 mg), the platelet counts increased. However, due to deteriorating renal function and progressive proteinuria, indicating lupus activation, mycophenolate mofetil treatment was initiated. In January 2014 he was hospitalized again because of recurrent deep vein thrombosis in his right superficial femoral vein. Low molecular weight heparin (LMWH) therapy was administered. The therapy was modified due to recurrent thromboses and activation of SLE: cyclophosphamide was initiated; in turn, the proteinuria diminished and the renal function improved slightly.
In March 2014 he was hospitalized for the next cycle of cyclophosphamide therapy. However, ultimately he could not be given it because of the progressive decreasing platelet count. Regarding his physical status, swollen lilac lips, epigastric pain, oedema of the lower right extremity and diarrhoea were observed. The laboratory test showed high CRP levels (90.51 mg/mL; normal range In the next few days the gastrointestinal symptoms diminished; however, the renal failure, anaemia and thrombocytopenia progressed and in the quantitative blood smear fragmentocytes were detected. Subsequently, paresis of the left upper extremity appeared. Skull computed tomography (CT) showed ischaemic lesion at regions of the right medial cerebral artery (Figure 1(a) ). Due to exceeding gastrointestinal pain, abdominal CT was performed, which detected thrombus in the lumen of the coeliac trunk (Figure 1(b) ), infarction in the spleen (Figure 1(c) ) and in the right kidney (Figure 1(d) ). Laboratory tests revealed antidsDNA and ab2GPI positivities. As a differential diagnosis thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome was considered; however, it was ruled out by the negative results on ADAMTS 13 and anti-factor H antibody assessment, respectively. Renal biopsy revealed thrombotic nephropathy. Special (trichrome) staining confirmed the presence of microthrombi which occluded the glomerular capillaries and arterioles ( Figure 2(c and d) ). Overall, the biopsy specimen was identified as class IIb lupus nephritis of the International Society of Nephrology/Renal Pathology Society classifications, 20, 21 chronic mesangioproliferative glomerular damage exhibiting thrombotic occlusions of the capillary tufts reflecting SLE-associated CAPS (Figure 2(a-d) ). Immunofluorescent staining for fibrin seen on Figure 2 (b) confirmed that the glomerular capillary tuft occlusions (long arrows) and the interstitial vascular obstructions (thick arrows) correspond to multiple fibrin-rich thrombi (green fluorescence), suggestive of a renal manifestation of CAPS. Electron microscopy also exhibited glomeruli with basement membrane (BM) thickening and endothelial-subendothelial damage associated with CAPS ( Figure 3) . Moreover, higher magnification on electron microscopy (10,000Â, Figure 3 
Summary diagnosis and treatments with follow-up
Based on the clinical features together with the applied histology and laboratory findings we could establish that CAPS on the grounds of SLE, which was induced by gastrointestinal infection, most likely developed by perpetuating the complement cascade activation with T and B-lymphocytes mobilization, resulting in multiple thromboses and consecutive ischaemic tissue damage in an amplified fashion.
The primary goal of the therapeutic plan was to decelerate the thrombotic cascade and to suppress inflammatory cytokines. LMWH treatment was continued but in lower dosage (2 Â 0.2 ml) in order to avoid bleeding in the ischaemic lesion of the territory at the right medial cerebral artery. The dose of corticosteroid was increased to 80 mg per day. Plasma exchange treatment (40 ml/kg) was performed six times. Haemodiafiltration treatment was performed three times because of the acute renal failure and increasing levels of carbamide and creatinine. After six plasma exchange cycles, along with the corticosteroid and LMWH treatment, the paresis resolved slightly and the haematological parameters began to normalize. However, no significant improvement could be achieved in renal function. The therapeutic regime was therefore supplemented with rituximab; 1000 mg of rituximab was given two times and the treatment led to a significant improvement of the acute renal failure, showing the efficacy of therapy on renal failure. After 5 weeks the patient was discharged from hospital with normal laboratory parameters and good general health. After 1 year the patient had a grand mal seizure at home and was admitted to our intensive care unit. Vasculitis, bleeding or a new thrombotic event could not be detected on magnetic resonance imaging. EEG detected epileptic activity; aPL were negative. The therapy was supplemented by carbamazepine. He was discharged from hospital after 1 week in a good overall condition.
Discussion
This complex case shows multi-organ thrombotic escalation. We believe that in this patient the concomitant infection initiated pathological processes, such as binding of aPL to the endothelium, followed by complement activation. The accelerated complement activation, therefore, as a second hit led to the development of catastrophic thrombotic manifestations. We also showed the intrarenal accumulation of lymphocytes, both T and B-cells, assuming that these cells also play a role in the development of renal pathology. These findings may explain the favourable effect of rituximab treatment on renal function, which is beneficial for decelerating lupus-associated humoral autoimmune processes, as well as the CAPS-associated pro-thrombotic aPL production. In our case immunohistochemistry reinforced the double-hit theory in CAPS development, identifying the presence of complements, as well as B-cells intrarenally, giving rise to the beneficial effects of using plasma exchange and rituximab in the disease management.
In the standard management of CAPS anticoagulation, corticosteroids, plasma exchange and immune-modulatory treatment is utilized, as well as the targeted therapy of other aetiological factors (e.g. infections) is pivotal. However, in certain cases, the modulation or depletion of B-cells can be necessary, as the source of autoantibodies and pro-inflammatory cytokines. 7 According to the CAPS registry only 20 cases treated with rituximab have been reported so far. 8 In most cases it was a second line treatment, based on poor therapeutic response to first line therapy. In four cases rituximab was the first line therapy because of associated lymphoma or very severe other life-threatening medical conditions. Among the patients treated with rituximab, the mortality decreased to 20%, i.e. four out of 20 died. 8 
Conclusion
We believe that in our patient, the identification of intrarenal complement activation and T/B lymphocytic infiltration along with disseminated microthrombus formation aid in understanding the pathomechanism of lupus-associated CAPS triggered by infection. According to the histological The beneficial effect of rituximab treatment Á Diószegi et al.
features at molecular and cellular levels, a combination therapy including rituximab treatment was used successfully, due to non-responding acute renal failure. After rituximab treatment the aPL profile has been changed. According to data from the CAPS registry the effect of rituximab on aPL was controversial. In most cases the antibody profile did not change after rituximab treatment. Overall, we suggest that in these patients B-cell depletion and/or plasma cell modulation can be considered, which may be just as beneficial for the outcome of the disease.
